Spine Tech and Orquest to combine technologies
This article was originally published in Clinica
Executive Summary
Spine Tech is to file an IDE with the US FDA to evaluate its spinal fusion devices (BAK) with Orquest's resorbable bone grafting material (Healos). Orquest's product is a porous matrix of collagen impregnated with resorbable hydroxyapatite that provides a scaffold for bone formation. The two companies plan to evaluate the material with Spine-Tech's hollow, threaded titanium alloy cylinders, which can be implanted in the spaces between vertebrae in the lumbar spine. Currently, some 80 per cent of bone grafting procedures harvest the patient's own bone, causing pain and long, expensive hospital stays.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.